Healthy Lifestyle Cuts CV Risk in Type 2 Diabetes, Even With GLP-1 Use

Adults living with type 2 diabetes who consistently engage in healthy lifestyle habits—including a plant-rich diet, regular physical activity, and sufficient sleep—experience a significantly reduced risk of cardiovascular events, a recent study indicates. Importantly, these benefits appear to hold true regardless of whether or not they are also using GLP-1 receptor agonist medications, a newer class of drugs gaining prominence in diabetes and weight management. The findings, published in Endocrine Today on March 9, 2026, underscore the enduring importance of foundational health behaviors even in the context of advanced pharmacological interventions.

Researchers from Harvard T.H. Chan School of Public Health, led by Dr. Frank Hu, analyzed data from nearly 100,000 participants enrolled in the U.S. Veterans Affairs Million Veteran Program between January 2011 and September 2023. The prospective cohort study assessed the association between adherence to eight specific healthy lifestyle factors and the incidence of major adverse cardiovascular events (MACE), encompassing stroke, heart attack, and cardiovascular death.

Defining ‘Healthy’ in the Study

The eight lifestyle habits evaluated were:

A high score on the Plant Diet Index, indicating a diet rich in plant-based foods.
At least 7.5 hours per week of physical activity equivalent to moderate intensity.
Non-smoking status.
Moderate alcohol consumption (avoiding heavy drinking).
7-9 hours of sleep per night.
Absence of opioid use disorder.
Effective stress management.
A high social interaction score.

The study found a clear dose-response relationship: the more healthy habits individuals adopted, the lower their risk of cardiovascular events. Those who consistently practiced all eight habits experienced a 60% reduction in risk compared to those reporting zero or one. This benefit was observed even among individuals already receiving GLP-1 receptor agonist therapy. GLP-1 receptor agonists, like semaglutide and liraglutide, have demonstrated significant efficacy in improving glycemic control and promoting weight loss, but this research suggests they are most effective when combined with lifestyle modifications.

GLP-1s and Lifestyle: A Synergistic Effect

Approximately 14% of the study cohort were using a GLP-1 receptor agonist. Researchers found that GLP-1 use was associated with an overall 16% reduction in MACE risk. But, the most substantial risk reduction was observed in individuals who combined GLP-1 therapy with six to eight healthy lifestyle habits—a 43% risk reduction compared to those not using a GLP-1 and reporting three or fewer healthy habits. This suggests a synergistic effect, where the benefits of medication and lifestyle interventions are amplified when used together.

“Even in the era of highly effective GLP-1-based pharmacotherapy, lifestyle remains fundamental to diabetes management and can substantially amplify CV benefits,” Dr. Hu told Healio. “Continued counseling and structured support for diet, physical activity, weight control and smoking cessation remain essential, as healthy habits appear to amplify the CV benefits of GLP-1 treatment.”

Study Limitations and Considerations

It’s important to note the study’s limitations. The observational nature of the research means it cannot definitively prove causation. Whereas the findings demonstrate a strong association between lifestyle habits and cardiovascular risk, it’s possible that other unmeasured factors contributed to the observed benefits. The study relied on self-reported data, which is subject to recall bias. The study population consisted primarily of veterans, which may limit the generalizability of the findings to other populations. The Million Veteran Program also doesn’t capture detailed information on the *quality* of dietary patterns beyond the Plant Diet Index score.

Cardiovascular Risk in Type 2 Diabetes: A Broader Context

Individuals with type 2 diabetes face a significantly elevated risk of cardiovascular disease compared to those without the condition. This increased risk stems from a complex interplay of factors, including insulin resistance, chronic inflammation, and dyslipidemia (abnormal blood lipid levels). Cardiovascular disease is the leading cause of death among people with diabetes, accounting for approximately 65% of fatalities. The Centers for Disease Control and Prevention (CDC) provides comprehensive information on heart disease, and diabetes.

While medications like GLP-1 receptor agonists and SGLT2 inhibitors have emerged as powerful tools for reducing cardiovascular risk in people with type 2 diabetes, lifestyle interventions remain a cornerstone of management. These interventions address the underlying metabolic and inflammatory processes that contribute to cardiovascular disease, offering a holistic approach to risk reduction.

What’s Next: Integrating Lifestyle and Pharmacotherapy

Dr. Hu suggests that future research should focus on evaluating the effectiveness of combining structured lifestyle interventions with GLP-1 therapy in real-world settings. Randomized controlled trials are needed to confirm whether this integrated approach can lead to even greater cardiovascular benefits than either strategy alone. Research is needed to identify the most effective strategies for promoting and sustaining long-term lifestyle changes in individuals with type 2 diabetes. The focus is shifting toward personalized approaches that consider individual preferences, cultural factors, and socioeconomic circumstances to maximize adherence and impact.

The U.S. Department of Veterans Affairs is actively exploring ways to integrate lifestyle counseling and support services into routine diabetes care. This includes offering nutrition education, exercise programs, and stress management workshops to veterans with type 2 diabetes. These efforts aim to empower individuals to take an active role in managing their health and reducing their risk of cardiovascular complications.